Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking and impact their ability to go about their daily lives. By applying our novel approach, we believe the synaptic dysfunction responsible for disease symptoms and progression can be reversed before the death of nerve cells.
Our Approach
HOPE THROUGH SCIENCE
We are developing neflamapimod – an investigational, orally administered, small molecule brain penetrant that inhibits the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical and clinical data with neflamapimod, including our ongoing Phase 2 RewinD-LB trial in patients with dementia with Lewy bodies (DLB), suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies development of symptoms and disease progression in the early stages of many neurological disorders.
PipelineInnovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP by joint consensus —
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a
